FLUBLOK QUADRIVALENT: payments to doctors
Payments that named FLUBLOK QUADRIVALENT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $439K
- Providers
- 8,099
- Transactions
- 9,923
- Average per transaction
- $44
The per-transaction average — $44 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,099 providers the average total is $54, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi Pasteur Inc. | $437,900 | 99.7% |
| Sanofi-aventis U.S. LLC | $1,377 | 0.3% |
| Vaxserve Inc. | $14 | 0.0% |